Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. Show more

Location: 18702 North Creek Parkway, Bothell, WA, 98011, United States | Website: https://immunome.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

2.337B

52 Wk Range

$5.15 - $25.30

Previous Close

$21.18

Open

$21.36

Volume

353,231

Day Range

$21.00 - $21.65

Enterprise Value

2.068B

Cash

272.6M

Avg Qtr Burn

-46.26M

Insider Ownership

7.86%

Institutional Own.

82.05%

Qtr Updated

09/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Varegacestat (AL102) (Gamma Secretase Inhibitor) Details Desmoid Tumors	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Varegacestat (Gamma Secretase Inhibitor) Details Desmoid Tumors	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMM-BCP-01 Details COVID-19	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.